GX-03 — FDA meeting
Q4 2026
Moderate-to-Severe Atopic Dermatitis (AD) Q1 2027: Topline Readout Q4 2026: FDA Type B Meeting Mid-2027: Phase 3 initiationSource filing
TTRX biotech catalysts & pipeline
TURN THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
GX-03 — Topline data
Q1 2027
Moderate-to-Severe Atopic Dermatitis (AD) Q1 2027: Topline ReadoutSource filing
GX-03 — Clinical data readout
Q4-2027
Phase 3 readout from Eczema Q4-2027Source filing
GX-03 — Interim data
Q1-2028
Interim Assessment from Phase 3 Onychomycosis Q1-2028Source filing